18:22 , May 7, 2019 |  BC Extra  |  Clinical News

May 7 Clinical Quick Takes: AZ, Merck, Osmotica, AlzeCure

AZ's Calquence meets in Phase III for CLL  AstraZeneca plc (LSE:AZN; NYSE:AZN) said an interim analysis of the Phase III ASCEND trial to treat relapsed or refractory chronic lymphocytic leukemia showed that Calquence acalabrutinib as...
22:27 , Nov 6, 2018 |  BioCentury  |  Finance

Advancing AlzeCure

Stockholm-based AlzeCure Pharma AB is planning to raise SEK200 million ($22 million) in an IPO on NASDAQ First North Premier to bring both arms of its Alzheimer’s disease portfolio to the clinic. In a prospectus...